{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:31:53Z","timestamp":1791185513312,"version":"4.1.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To evaluate the relevance of directing antigen-specific CD4+ T helper cells as part of effective anticancer immunotherapy, we investigated the immunologic and clinical responses to vaccination with dendritic cells (DC) pulsed with either MHC class I (MHC-I)\u2013restricted epitopes alone or both MHC class I and II (MHC-I\/II)\u2013restricted epitopes. We enrolled 33 stage III and IV HLA-A*02:01\u2013positive patients with melanoma in this study, of whom 29 were evaluable for immunologic response. Patients received intranodal vaccinations with cytokine-matured DCs loaded with keyhole limpet hemocyanin and MHC-I alone or MHC-I\/II\u2013restricted tumor-associated antigens (TAA) of tyrosinase and gp100, depending on their HLA-DR4 status. In 4 of 15 patients vaccinated with MHC-I\/II\u2013loaded DCs and 1 of 14 patients vaccinated with MHC-I\u2013loaded DCs, we detected TAA-specific CD8+ T cells with maintained IFN-\u03b3 production in skin test infiltrating lymphocyte (SKIL) cultures and circulating TAA-specific CD8+ T cells. If TAA-specific CD4+ T-cell responses were detected in SKIL cultures, it coincided with TAA-specific CD8+ T-cell responses. In 3 of 13 patients tested, we detected TAA-specific CD4+CD25+FoxP3\u2212 T cells with high proliferative capacity and IFN-\u03b3 production, indicating that these were not regulatory T cells. Vaccination with MHC-I\/II\u2013loaded DCs resulted in improved clinical outcome compared with matched control patients treated with dacarbazine (DTIC), median overall survival of 15.0 versus 8.3 months (P = 0.089), and median progression-free survival of 5.0 versus 2.8 months (P = 0.0089). In conclusion, coactivating TAA-specific CD4+ T-helper cells with DCs pulsed with both MHC class I and II\u2013restricted epitopes augments TAA-specific CD8+ T-cell responses, contributing to improved clinical responses. Cancer Res; 73(1); 19\u201329. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-12-1127","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T21:32:35Z","timestamp":1350682355000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell\u2013Based Vaccination"],"prefix":"10.1158","volume":"73","author":[{"given":"Erik H.J.G.","family":"Aarntzen","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"},{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"De Vries","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"},{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joost","family":"Lesterhuis","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danita","family":"Schuurhuis","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannes F.M.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"},{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"},{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalijn","family":"Bol","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"},{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Mus","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.W.","family":"De Wilt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Croockewit","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke A.M.","family":"Blokx","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Van Rossum","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Kwok","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosse J.","family":"Adema","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.A.","family":"Punt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl G.","family":"Figdor","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Tumor Immunology, 2Medical Oncology, 3Laboratory Medicine, 4Radiology, 5Surgery, 6Hematology, 7Pathology, 8Dermatology, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen; 9Divisions of Medical Oncology and Immunology, The Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; 10Academic Medical Centre, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; 11University Hospital Essen, Department of Dermatology, Essen, Germany; and 12Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,1,2]]},"reference":[{"key":"2022061703495512700_bib1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI0215962","article-title":"Exploiting dendritic cells to improve vaccine efficacy","volume":"109","author":"Steinman","year":"2002","journal-title":"J Clin Invest"},{"key":"2022061703495512700_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2007.12.007","article-title":"Dendritic cell vaccines in melanoma: from promise to proof?","volume":"66","author":"Lesterhuis","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022061703495512700_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann Oncol"},{"key":"2022061703495512700_bib4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"2022061703495512700_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.1999.tb01331.x","article-title":"Human tumor antigens for cancer vaccine development","volume":"170","author":"Wang","year":"1999","journal-title":"Immunol Rev"},{"key":"2022061703495512700_bib6","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.4049\/jimmunol.165.6.3492","article-title":"Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells","volume":"165","author":"Schuler-Thurner","year":"2000","journal-title":"J Immunol"},{"key":"2022061703495512700_bib7","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2003.04.042","article-title":"Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients","volume":"21","author":"Bedrosian","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061703495512700_bib8","first-page":"5091","article-title":"Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients","volume":"9","author":"de Vries","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061703495512700_bib9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20032118","article-title":"Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells","volume":"199","author":"Paczesny","year":"2004","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T","article-title":"Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells","volume":"86","author":"Mackensen","year":"2000","journal-title":"Int J Cancer"},{"key":"2022061703495512700_bib11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.192.11.1535","article-title":"Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells","volume":"192","author":"Berard","year":"2000","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib13","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.164.7.3902","article-title":"Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor","volume":"164","author":"Baxevanis","year":"2000","journal-title":"J Immunol"},{"key":"2022061703495512700_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"key":"2022061703495512700_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.0019-2805.2001.01343.x","article-title":"Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells","volume":"105","author":"Faiola","year":"2002","journal-title":"Immunology"},{"key":"2022061703495512700_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00251-006-0171-9","article-title":"Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines","volume":"59","author":"Rodriguez","year":"2007","journal-title":"Immunogenetics"},{"key":"2022061703495512700_bib17","first-page":"35","article-title":"MHC antigens in human melanomas","volume":"2","author":"Ruiter","year":"1991","journal-title":"Semin Cancer Biol"},{"key":"2022061703495512700_bib18","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1054\/bjoc.2001.2160","article-title":"gp100\/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells","volume":"85","author":"Kierstead","year":"2001","journal-title":"Br J Cancer"},{"key":"2022061703495512700_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20011974","article-title":"The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome","volume":"195","author":"Schultz","year":"2002","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib20","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.4049\/jimmunol.165.8.4731","article-title":"In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program","volume":"165","author":"Cochlovius","year":"2000","journal-title":"J Immunol"},{"key":"2022061703495512700_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nm1039","article-title":"Dendritic cell immunotherapy: mapping the way","volume":"10","author":"Figdor","year":"2004","journal-title":"Nat Med"},{"key":"2022061703495512700_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.2910620118","article-title":"Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line","volume":"62","author":"Bakker","year":"1995","journal-title":"Int J Cancer"},{"key":"2022061703495512700_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1126\/science.7513441","article-title":"Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines","volume":"264","author":"Cox","year":"1994","journal-title":"Science"},{"key":"2022061703495512700_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s002620050501","article-title":"Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells","volume":"47","author":"Li","year":"1998","journal-title":"Cancer Immunol Immunother"},{"key":"2022061703495512700_bib25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1084\/jem.183.5.1965","article-title":"Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes","volume":"183","author":"Topalian","year":"1996","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib26","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00262-012-1263-z","article-title":"Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters","volume":"61","author":"Aarntzen","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2022061703495512700_bib27","author":"Labtube.tv [internet]"},{"key":"2022061703495512700_bib28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/annonc\/mdl072","article-title":"Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests","volume":"17","author":"Lesterhuis","year":"2006","journal-title":"Ann Oncol"},{"key":"2022061703495512700_bib29","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1200\/JCO.2005.06.478","article-title":"Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome","volume":"23","author":"de Vries","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061703495512700_bib30","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061703495512700_bib31","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/j.1600-0625.2009.01055.x","article-title":"Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination","volume":"19","author":"Correll","year":"2010","journal-title":"Exp Dermatol"},{"key":"2022061703495512700_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1078-0432.CCR-10-2227","article-title":"Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents","volume":"17","author":"de Vries","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061703495512700_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-005-0056-z","article-title":"A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients","volume":"55","author":"Trakatelli","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"2022061703495512700_bib35","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1158\/1078-0432.CCR-06-1879","article-title":"Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients","volume":"12","author":"Lesimple","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061703495512700_bib36","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4049\/jimmunol.172.2.1304","article-title":"Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy","volume":"172","author":"Schultz","year":"2004","journal-title":"J Immunol"},{"key":"2022061703495512700_bib37","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2010.33.8053","article-title":"Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine","volume":"29","author":"Slingluff","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061703495512700_bib38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00002371-200307000-00007","article-title":"Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens","volume":"26","author":"Phan","year":"2003","journal-title":"J Immunother"},{"key":"2022061703495512700_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/01.cji.0000190399.98802.10","article-title":"Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"2022061703495512700_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.1100658","article-title":"MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells","volume":"187","author":"Erskine","year":"2011","journal-title":"J Immunol"},{"key":"2022061703495512700_bib41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni1490","article-title":"Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes","volume":"8","author":"Skokos","year":"2007","journal-title":"Nat Immunol"},{"key":"2022061703495512700_bib42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0197-2456(01)00143-X","article-title":"Uniform power method for sample size calculation in historical control studies with binary response","volume":"22","author":"Lee","year":"2001","journal-title":"Control Clin Trials"},{"key":"2022061703495512700_bib43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061703495512700_bib44","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061703495512700_bib45","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.4049\/jimmunol.180.5.3122","article-title":"Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells","volume":"180","author":"Wong","year":"2008","journal-title":"J Immunol"},{"key":"2022061703495512700_bib46","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2006-09-045245","article-title":"Adoptive transfer of tumor-primed, in vitro -activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"2022061703495512700_bib47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy - revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022061703495512700_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1084\/jem.186.1.65","article-title":"Induction of a CD8 +cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help","volume":"186","author":"Bennett","year":"1997","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.187.5.693","article-title":"Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors","volume":"187","author":"Ossendorp","year":"1998","journal-title":"J Exp Med"},{"key":"2022061703495512700_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V98.1.49","article-title":"Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells","volume":"98","author":"Van Tendeloo","year":"2001","journal-title":"Blood"},{"key":"2022061703495512700_bib51","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/0008-5472.CAN-08-3920","article-title":"In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients","volume":"69","author":"Schuurhuis","year":"2009","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/1\/19\/2683050\/19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/1\/19\/2683050\/19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T08:40:41Z","timestamp":1655455241000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/1\/19\/583993\/Targeting-CD4-T-Helper-Cells-Improves-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,2]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-12-1127","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22394405.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394402","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394405","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394402.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6504023.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6504023","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394414.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394408","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22394411.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}